Mounjaro Medicare Part D Coverage: What You Actually Pay in 2026

How Medicare Part D Handles Tirzepatide Right Now

Most Medicare Part D plans cover Mounjaro when prescribed for its FDA-approved type 2 diabetes indication. Coverage is not guaranteed for weight management, because Medicare statute has historically excluded drugs used solely for obesity. That changed partially with the Treat and Reduce Obesity Act discussions in Congress, but as of mid-2026, plan-by-plan variability remains the norm for obesity-only prescriptions.

The Diabetes vs. Obesity Distinction

The FDA approved tirzepatide under two brand names: Mounjaro for type 2 diabetes (May 2022) and Zepbound for chronic weight management (November 2023) [1]. Medicare Part D plans are required to cover medically necessary diabetes treatments. They are not required to cover anti-obesity medications under the standard benefit structure. If your prescriber documents a type 2 diabetes diagnosis with an HbA1c at or above 7%, most plans will process the claim.

Formulary Tier Placement

Where tirzepatide lands on your plan's formulary affects your copay directly. Most Part D plans place Mounjaro on Tier 3 (preferred brand) or Tier 4 (non-preferred specialty). A Tier 3 placement might mean a $47 copay per fill after deductible, while Tier 4 can push the cost to 25-33% coinsurance on the negotiated price. The Centers for Medicare & Medicaid Services (CMS) publishes each plan's formulary annually through the Medicare Plan Finder tool, and checking your specific plan's tier placement before filling is worth the five minutes it takes.

Prior Authorization and Step Therapy

Nearly every Part D plan requires prior authorization for tirzepatide. Common criteria include a documented HbA1c of 7% or higher, trial and failure of metformin (unless contraindicated), and prescriber attestation that the patient has type 2 diabetes [2]. Some plans also impose step therapy, requiring documented use of a GLP-1 receptor agonist like semaglutide or dulaglutide before approving tirzepatide. Your prescriber's office handles the PA submission, but knowing your plan's requirements speeds the process.

The $2,000 Out-of-Pocket Cap Changes the Math

The Inflation Reduction Act (IRA) restructured Medicare Part D cost-sharing beginning January 1, 2025. The most significant change for expensive brand-name drugs is the hard annual out-of-pocket cap of $2,000 [3]. Before this cap, beneficiaries in the catastrophic coverage phase still owed 5% coinsurance on high-cost drugs indefinitely. That 5% on a $1,023 monthly drug added up fast.

What This Means for Mounjaro Specifically

Under the new structure, a beneficiary filling Mounjaro at a plan-negotiated price of around $900 per month would hit the $2,000 cap within roughly two to three months of fills (after the deductible phase). For the remaining nine to ten months of the year, the beneficiary pays $0 for Mounjaro. Spread across twelve months using CMS's Medicare Prescription Payment Plan (the "smoothing" option), this works out to approximately $167 per month [3].

How to Elect the Payment Smoothing Option

CMS introduced the Medicare Prescription Payment Plan in 2025, which lets beneficiaries spread their out-of-pocket costs across the calendar year in predictable monthly installments rather than paying large sums at the pharmacy counter during the deductible and initial coverage phases. You can elect this option by contacting your Part D plan directly or enrolling through Medicare.gov. The program does not reduce total costs. It redistributes them, which matters when the alternative is a $400+ pharmacy bill in January.

Why Mounjaro's Cash Price Sits at $1,023

Eli Lilly set Mounjaro's wholesale acquisition cost (WAC) at $1,023.04 for a four-week supply across all dose strengths [4]. This pricing positions tirzepatide in the same range as semaglutide 2.4 mg (Wegovy), which lists at $1,349.02 per month. The actual price a Part D plan pays after rebates and negotiation is lower, but those savings flow to the plan and PBM rather than directly to the patient.

The Rebate Black Box

Pharmacy benefit managers (PBMs) negotiate confidential rebates with manufacturers. For GLP-1 receptor agonists, estimated rebates range from 20% to 40% of list price according to drug pricing analysts. The IRA's Medicare Drug Price Negotiation Program selected the first 10 drugs for negotiation in 2023, and additional drugs are being added in subsequent years. Tirzepatide is not yet among the negotiated drugs, but its high Medicare spending makes future selection likely [5].

Compounded Tirzepatide as an Alternative

Compounding pharmacies have offered tirzepatide preparations at an average cost of roughly $249 per month during the FDA-recognized shortage period. The FDA added tirzepatide to the drug shortage list in late 2023 [6]. When a drug is on the shortage list, 503A and 503B compounding pharmacies may legally produce copies. If the FDA resolves the shortage designation, the legal basis for compounding shifts, and availability may narrow. Medicare Part D plans do not typically cover compounded drugs, so this option is a cash-pay alternative rather than an insurance play.

Step-by-Step: Getting Mounjaro Covered Under Your Part D Plan

The process from prescription to filled syringe involves several checkpoints. Knowing each one reduces delays and surprise costs.

Step 1: Confirm Your Diagnosis Code

Your prescriber must use ICD-10 code E11.x (type 2 diabetes mellitus) on the prescription and any PA paperwork. An E66.x code (obesity) without a diabetes diagnosis will almost certainly trigger a rejection under most Part D plans.

Step 2: Check Your Formulary

Log into your Part D plan's member portal or call the number on your card to confirm tirzepatide is on formulary and which tier it occupies. If it is listed as non-formulary or excluded, your prescriber can submit a formulary exception request.

Step 3: Prior Authorization Submission

Your prescriber's office submits the PA to the plan, typically via CoverMyMeds or a plan-specific electronic portal. Turnaround is usually 24-72 hours for standard requests. Expedited requests (for urgent clinical situations) must be decided within 24 hours under CMS rules.

Step 4: Appeal if Denied

If the PA is denied, you have the right to a coverage determination appeal. The first level is a plan redetermination (decided within 7 days for standard, 72 hours for expedited). The second level goes to an Independent Review Entity. Data from CMS show that roughly 40-50% of Part D appeals are decided in the beneficiary's favor at the redetermination level [7].

Step 5: Fill and Track Your OOP Spending

Once approved, fill at a plan-preferred pharmacy (often a mail-order option for specialty drugs). Track your out-of-pocket spending against the $2,000 cap. Your plan's Explanation of Benefits (EOB) statements and the Medicare.gov portal both show running totals.

Comparing Part D Plans During Open Enrollment

Medicare Annual Enrollment runs October 15 through December 7 each year. This is the only regular window to switch Part D plans without a qualifying life event. For a beneficiary taking tirzepatide, plan selection can swing annual out-of-pocket costs by hundreds of dollars.

Factors That Matter Most

Three variables drive your real cost: the plan's deductible (ranging from $0 to $590 in 2026), the tier and copay/coinsurance structure for tirzepatide, and whether the plan's preferred pharmacy network includes convenient options. A plan with a $0 deductible but Tier 4 placement for Mounjaro may cost more in total than a plan with a $590 deductible and Tier 3 placement.

Using the Medicare Plan Finder

The CMS Medicare Plan Finder lets you enter your zip code and drug list to compare estimated annual costs across available Part D plans. Enter "tirzepatide" or "Mounjaro" with the prescribed dose, and the tool estimates monthly and annual out-of-pocket costs specific to each plan. Run this comparison every October, because plan formularies and tier placements change annually.

Manufacturer Programs and Their Medicare Limitations

Eli Lilly operates the Mounjaro Savings Card for commercially insured patients, offering copays as low as $25 per fill. This program explicitly excludes Medicare beneficiaries. Federal anti-kickback statute prohibits pharmaceutical manufacturers from subsidizing cost-sharing for patients in federal healthcare programs, including Medicare Part D [8].

What Eli Lilly Does Offer Medicare Patients

Eli Lilly's Lilly Patient Assistance Program (PAP) provides Mounjaro at no cost to qualifying Medicare beneficiaries who meet income criteria (typically at or below 400% of the federal poverty level, approximately $62,400 for a single individual in 2026). The application requires documentation of Medicare enrollment, income verification, and a valid prescription. Processing takes two to four weeks.

Dr. Robert Gabbay, Chief Scientific and Medical Officer of the American Diabetes Association, has stated: "Access to newer diabetes medications like tirzepatide should not depend on a patient's insurance tier or ability to manage prior authorization barriers" [9]. The ADA's 2024 Standards of Care recommend tirzepatide as a treatment option for type 2 diabetes with overweight or obesity, further strengthening the clinical case for Part D coverage requests [10].

State Pharmaceutical Assistance Programs (SPAPs)

Twenty-three states operate SPAPs that supplement Medicare Part D by covering premiums, deductibles, or copays for qualifying residents. Programs in New York (EPIC), Pennsylvania (PACE/PACENET), and Connecticut (ConnPACE) are among the most established. Eligibility rules and covered drugs vary. Check your state's pharmaceutical assistance program through the Medicare.gov resource page or by calling 1-800-MEDICARE.

The Clinical Case for Tirzepatide Coverage

The strength of the evidence behind tirzepatide is relevant to coverage decisions because Part D plans weigh clinical data when making formulary placements and PA criteria.

SURPASS Trials for Type 2 Diabetes

The SURPASS program, a series of phase 3 trials, established tirzepatide's efficacy in type 2 diabetes. In SURPASS-1 (N=478), tirzepatide 15 mg reduced HbA1c by 2.07% from baseline versus 0.04% with placebo at 40 weeks [11]. SURPASS-2 (N=1,879) compared tirzepatide to semaglutide 1 mg and demonstrated superior HbA1c reduction (2.46% vs. 1.86%) and greater weight loss (12.4 kg vs. 6.2 kg) at 40 weeks [12].

SURMOUNT Trials for Weight Management

SURMOUNT-1 (N=2,539) randomized adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity to tirzepatide or placebo. At 72 weeks, the 15 mg dose group lost 22.5% of body weight compared to 2.4% in the placebo group [13]. This magnitude of weight loss exceeds results from STEP-1 (semaglutide 2.4 mg, 14.9% at 68 weeks) and approaches outcomes previously seen only with bariatric surgery.

The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity recommends tirzepatide as a first-line option for patients with BMI ≥30 or BMI ≥27 with comorbidities, citing the SURMOUNT data [14].

Why This Matters for Your PA

When a prior authorization is denied or a formulary exception is needed, your prescriber can cite these trial results in the appeal letter. Demonstrating that tirzepatide offers superior glycemic control and weight reduction compared to other covered GLP-1 agents strengthens the medical necessity argument. Include the SURPASS-2 head-to-head data showing superiority over semaglutide if the plan is directing you toward a different GLP-1 first.

What Could Change: Legislative and Regulatory Outlook

The Treat and Reduce Obesity Act, reintroduced in Congress in 2024 and again in 2025, would require Medicare Part D to cover FDA-approved anti-obesity medications. If enacted, this would expand tirzepatide (under the Zepbound label) coverage to Medicare beneficiaries with obesity who do not have a type 2 diabetes diagnosis [15]. The Congressional Budget Office has not released a final cost estimate for the current version.

CMS also has the authority to issue guidance on coverage criteria through National Coverage Determinations (NCDs). No NCD currently addresses GLP-1 receptor agonists for obesity specifically. Any future NCD or legislative change would take effect no earlier than the following plan year.

Dr. Fatima Cody Stanford, an obesity medicine physician at Massachusetts General Hospital, noted in a 2024 interview: "Medicare's exclusion of anti-obesity medications is a relic of outdated thinking that treats obesity as a lifestyle choice rather than a chronic disease. The science no longer supports that distinction" [16].